Aldehyde dehydrogenase activation prevents reperfusion arrhythmias by inhibiting local renin release from cardiac mast cells

Circulation

Volumn 122, Issue 8, 2010, Pages 771-781

  Koda, Kenichiro ^a   Salazar Rodriguez, Mariselis ^a   Corti, Federico ^a   Chan, Noel Yan Ki ^a   Estephan, Racha ^a   Silver, Randi B ^a   Mochly Rosen, Daria ^b   Levi, Roberto ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Arrhythmia; Ischemia; Norepinephrine; Renin; Reperfusion

Indexed keywords

ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ALDEHYDE DEHYDROGENASE; BETA N ACETYLHEXOSAMINIDASE; GLYCERYL TRINITRATE; NORADRENALIN; PROTEIN KINASE C EPSILON; RENIN; RNA;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ASSAY; EX VIVO STUDY; GUINEA PIG; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HUMAN CELL; IMMUNOBLOTTING; ISCHEMIC PRECONDITIONING; MAST CELL; NONHUMAN; NORADRENALIN RELEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN RELEASE; REPERFUSION INJURY; ANIMAL; DEGRANULATION; DRUG ANTAGONISM; HEART INFARCTION PREVENTION; HEART MUSCLE CELL; MALE; METABOLISM; PHYSIOLOGY; SECRETION; TUMOR CELL LINE;

ALDEHYDE DEHYDROGENASE; ANIMALS; ARRHYTHMIAS, CARDIAC; CELL DEGRANULATION; CELL LINE, TUMOR; ENZYME ACTIVATION; GUINEA PIGS; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; MAST CELLS; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; PROTEIN KINASE C-EPSILON; RECEPTOR, ADENOSINE A2B; RECEPTOR, ADENOSINE A3; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 77956631792     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.952481     Document Type: Article

References (52)

1. Reid AC, Silver RB, LeviR. Renin: at the heart of the mast cell. Immunol Rev. 2007;217:123-140.
2. Silver RB, Reid AC, Mackins CJ, Askwith T, Schaefer U, Herzlinger D, Levi R. Mast cells: a unique source of renin. Proc Natl Acad Sci USA. 2004;101:13607-13612.
3. Mackins CJ, Kano S, Seyedi N, Schafer U, Reid AC, Machida T, Silver RB, Levi R. Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release, and arrhythmias in ischemia/reperfusion. J Clin Invest. 2006;116:1063-1070.
4. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986; 74:1124-1136.
5. Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev. 2008;88:581-609.
6. Cohen MV, Downey JM. Adenosine: trigger and mediator of cardiopro-tection. Basic Res Cardiol. 2008;103:203-215.
7. Gross GJ, Auchampach JA. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res. 1992; 70:223-233.
8. Peart JN, Headrick JP. Adenosinergic cardioprotection: multiple receptors, multiple pathways. Pharmacol Ther. 2007;114:208-221.
9. Liu GS, Cohen MV, Mochly-Rosen D, Downey JM. Protein kinase C-e is responsible for the protection of preconditioning in rabbit cardiomyo-cytes. J Mol Cell Cardiol. 1999;31:1937-1948.
10. Inagaki K, Begley R, Ikeno F, Mochly-Rosen D. Cardioprotection by epsilon-protein kinase C activation from ischemia: continuous delivery and antiarrhythmic effect of an epsilon-protein kinase C-activating peptide. Circulation. 2005;111:44-50.
11. Ozawa K, Yamada K, Kazanietz MG, Blumberg PM, Beaven MA. Different isozymes of protein kinase C mediate feedback inhibition of phos-pholipase C and stimulatory signals for exocytosis in rat RBL-2H3 cells. J Biol Chem. 1993;268:2280-2283.
12. Chen CH, Budas GR, Churchill EN, Disatnik MH, Hurley TD, Mochly-Rosen D. Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science. 2008;321:1493-1495.
13. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med. 1991;11:81-128.
14. Cordis GA, Maulik N, Bagchi D, Engelman RM, Das DK. Estimation of the extent of lipid peroxidation in the ischemic and reperfused heart by monitoring lipid metabolic products with the aid of high-performance liquid chromatography. J Chromatogr. 1993;632:97-103.
15. Eaton P, Li JM, Hearse DJ, Shattock MJ. Formation of 4-hydroxy-2-nonenal- modified proteins in ischemic rat heart. Am J Physiol. 1999;276: H935-H943.
16. Churchill EN, Disatnik MH, Mochly-Rosen D. Time-dependent and ethanol-induced cardiac protection from ischemia mediated by mitochondrial translocation of varepsilonPKC and activation of aldehyde dehydrogenase 2. J Mol Cell Cardiol. 2009;46:278-284.
17. Liu Y, Tsuchida A, Cohen MV, Downey JM. Pretreatment with angiotensin II activates protein kinase C and limits myocardial infarction in isolated rabbit hearts. J Mol Cell Cardiol. 1995;27:883-892.
18. Diaz RJ, Wilson GJ. Selective blockade of AT1 angiotensin II receptors abolishes ischemic preconditioning in isolated rabbit hearts. J Mol Cell Cardiol. 1997;29:129-139.
19. Das S, Otani H, Maulik N, Das DK. Redox regulation of angiotensin II preconditioning of the myocardium requires MAP kinase signaling. J Mol Cell Cardiol. 2006;41:248-2455.
20. 2B adenosine receptors. J Med Chem. 2000;43: 1165-1172.
21. 3 adenosine receptor antagonists. J Med Chem. 1998;41:3186-3201.
22. 2B adenosine receptor agonists. Purinergic Signal. 2008;4:287-303.
23. 2 receptor activation. Circ Res. 1997;81:415-422.
24. Kobayashi T, Ikeda K, Kumanishi T. Functional characterization of an endogenous Xenopus oocyte adenosine receptor. Br J Pharmacol. 2002; 135:313-322.
25. Grover GJ, Garlid KD. ATP-sensitive potassium channels: a review of their cardioprotective pharmacology. J Mol Cell Cardiol. 2000;32: 677-695.
26. Cohen MV, Yang XM, Liu GS, Heusch G, Downey JM. Acetylcholine, bradykinin, opioids, and phenylephrine, but not adenosine, trigger preconditioning by generating free radicals and opening mitochondrial K(ATP) channels. Circ Res. 2001;89:273-278.
27. Li X, Rapedius M, Baukrowitz T, Liu GX, Srivastava DK, Daut J, Hanley PJ. 5-Hydroxydecanoate and coenzyme A are inhibitors of native sar-colemmal KATP channels in inside-out patches. Biochim Biophysic Acta. 2010;1800:385-391.
28. Chang RS, Siegl PK, Clineschmidt BV, Mantlo NB, Chakravarty PK, Greenlee WJ, Patchett AA, Lotti VJ. In vitro pharmacology of L-158,809, a new highly potent and selective angiotensin II receptor antagonist. J Pharmacol Exp Ther. 1992;262:133-138.
29. Downey JM, Davis AM, Cohen MV. Signaling pathways in ischemic preconditioning. Heart Fail Rev. 2007;12:181-188.
30. Ping P, Zhang J, Qiu Y, Tang XL, Manchikalapudi S, Cao X, Bolli R. Ischemic preconditioning induces selective translocation of protein kinase C isoforms epsilon and eta in the heart of conscious rabbits without subcellular redistribution of total protein kinase C activity. Circ Res. 1997;81:404-414.
31. Jaburek M, Costa AD, Burton JR, Costa CL, Garlid KD. Mitochondrial PKC epsilon and mitochondrial ATP-sensitive K+ channel copurify and coreconstitute to form a functioning signaling module in proteoliposomes. Circ Res. 2006;99:878-883.
32. Inagaki K, Hahn HS, Dorn GW, Mochly-Rosen D. Additive protection of the ischemic heart ex vivo by combined treatment with delta-protein kinase C inhibitor and epsilon-protein kinase C activator. Circulation. 2003;108:869-875.
33. Johnson JA, Gray MO, Chen CH, Mochly-Rosen D. A protein kinase C translocation inhibitor as an isozyme-selective antagonist of cardiac function. J Biol Chem. 1996;271:24962-24966.
34. Ping P. Getting to the heart of proteomics. N Engl J Med. 2009;360: 532-534.
35. 3 adenosine receptors. Circ Res. 2003;92:485-492.
36. Dorn GW, Souroujon MC, Liron T, Chen CH, Gray MO, Zhou HZ, Csukai M, Wu G, Lorenz JN, Mochly-Rosen D. Sustained in vivo cardiac protection by a rationally designed peptide that causes epsilon protein kinase C translocation. Proc Natl Acad Sci USA. 1999;96:12798-12803.
37. Budas GR, Disatnik MH, Mochly-Rosen D. Aldehyde dehydrogenase 2 in cardiac protection: a new therapeutic target? Trends Cardiovasc Med. 2009;19:158-164.
38. Dostal DE, Baker KM. The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? Circ Res. 1999;85:643-650.
39. Campbell DJ. Critical review of prorenin and (pro)renin receptor research. Hypertension. 2008;51:1259-1264.
40. Barlucchi L, Leri A, Dostal DE, Fiordaliso F, Tada H, Hintze TH, Kajstura J, Nadal-Ginard B, Anversa P. Canine ventricular myocytes possess a renin-angiotensin system that is upregulated with heart failure. Circ Res. 2001;88:298-304.
41. 3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J Biol Chem. 1993;268:16887-16890.
42. 3 receptors: pharmacological properties, species differences and receptor functions. Trends Pharmacol Sci. 1994; 15:298-306.
43. Feoktistov I, Biaggioni I. Adenosine A2B receptors. Pharmacol Rev. 1997;49:381-402.
44. Fredholm BB, Abbracchio MP, Burnstock G, Daly JW, Harden TK, Jacobson KA, Leff P, Williams M. Nomenclature and classification of purinoceptors. Pharmacol Rev. 1994;46:143-156.
45. Headrick JP. Ischemic preconditioning: bioenergetic and metabolic changes and the role of endogenous adenosine. J Mol Cell Cardiol. 1996;28:1227-1240.
46. Hinschen AK, Rose'Meyer RB, Headrick JP. Adenosine receptor subtypes mediating coronary vasodilation in rat hearts. J Cardiovasc Pharmacol. 2003;41:73-80.
47. Hua X, Kovarova M, Chason KD, Nguyen M, Koller BH, Tilley SL. Enhanced mast cell activation in mice deficient in the A2b adenosine receptor. J Exp Med. 2007;204:117-128.
48. Ryzhov S, Zaynagetdinov R, Goldstein AE, Novitskiy SV, Blackburn MR, Biaggioni I, Feoktistov I. Effect of A2B adenosine receptor gene ablation on adenosine-dependent regulation of proinflammatory cyto-kines. J Pharmacol Exp Ther. 2008;324:694-700.
49. Kawano T, Matsuse H, Kondo Y, Machida I, Saeki S, Tomari S, Mitsuta K, Obase Y, Fukushima C, Shimoda T, Kohno S. Acetaldehyde induces histamine release from human airway mast cells to cause bronchocon-striction. Int Arch Allergy Immunol. 2004;134:233-239.
50. Auchampach JA, Bolli R. Adenosine receptor subtypes in the heart: therapeutic opportunities and challenges. Am J Physiol. 1999;276: H1113-H1116.
51. Wilson GJ, Diaz RJ. The myocardial no-reflow phenomenon: role of deltaPKC. Cardiovasc Res. 2007;73:623-625.
52. Downey JM, Cohen MV. Why do we still not have cardioprotective drugs? Circ J. 2009;73:1171-1177.